default author photo

Rashi Raghulan

Revolution Medicines Inc

Redwood City

United States

  • Revolution Medicines Inc

SCHOLARLY PAPERS

1

DOWNLOADS

70

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Anticancer Activity of RAS-GTP Inhibition in Cholangiocarcinoma

Number of pages: 56 Posted: 04 Jul 2025
Rodrigo Entrialgo-Cadierno, Konstantina Morali, Iker Feliu, Yingyun Wang, Jim Evans, Mariana Yañez-Bartolome, Ines Lopez, Irati Macaya, Cristina Cueto-Ureña, Yaiza Senent, Jose M. Herranz, Rashi Raghulan, Javier Vaquero, Jesus Maria Banales, Teresa Macarulla, Mariano Ponz-Sarvise, Ximo Pechuan-Jorge, Elisabeth Guruceaga, Tian Tian, Ida Aronchik, Mallika Singh, Jingjing Jiang, Silvestre Vicent and Sneak Peek Administrator
University of Navarra, University of Navarra, University of Navarra, Revolution Medicines Inc, Revolution Medicines Inc, Vall d’Hebron Institute of Oncology (VHIO), University of Navarra, University of Navarra, University of Navarra, University of Navarra, Vall d’Hebron Institute of Oncology (VHIO), Revolution Medicines Inc, University of Salamanca - CSIC, Cancer Research Center, Biogipuzkoa Health Research Institute, Vall d’Hebron Institute of Oncology (VHIO), Universidad de Navarra - Clinica Universidad de Navarra and Program in Solid Tumors (CIMA), Revolution Medicines Inc, University of Navarra, Vall d’Hebron Institute of Oncology (VHIO), Revolution Medicines Inc, Revolution Medicines Inc, Revolution Medicines Inc, University of Navarra and Independent
Downloads 70 (883,195)

Abstract:

Loading...

cholangiocarcinoma, KRAS oncogene, RAS-GTP inhibitors, resistance